vTv Therapeutics Presents Additional Positive Data from the Phase 2 Simplici-T1 Study in Patients with Type 1 Diabetes at 55t...
September 18 2019 - 7:30AM
vTv Therapeutics Inc. (Nasdaq: VTVT), today presented additional
positive data from its phase 2 Simplici-T1 study in patients
with type 1 diabetes (T1D) at the 55th Annual Meeting of the
European Association for the Study of Diabetes.
In a poster titled “Results from the sentinel and learning phase
of the Simplici-T1 study, the first clinical trial to test
activation of glucokinase as an adjunctive treatment for type 1
diabetes”, Dr. Carmen Valcarce, Chief Scientific Officer at vTv
Therapeutics presented new continuous glucose monitor (CGM) and
insulin dose data from the patients with complete CGM profiles in
the completed Phase 2 - Part 1 of the study. Key results
presented included:
- TTP399 treatment (n=6) increased Time in Range from baseline to
end of treatment by 11% (2.7 hours) (p=0.055) per day (24 hours),
and by 12% (1.7 hours) (p=0.04) during the critical waking hours
(7am-9pm) relative to placebo (n=9).
- TTP399 treatment reduced the total daily mealtime bolus insulin
dose by 23% compared to 4% for placebo while significantly
improving glycemic control.
- Patients in the treatment group experienced fewer Level 1
(≥54-70 mg/dl) and Level 2 (<54 mg/dl) hypoglycemic events than
patients in the placebo group.
“These new clinical data enhance the very promising topline
efficacy results we announced for this part of the study in June,
where TTP399 reduced HbA1c levels by 0.7% relative to placebo,”
said Steve Holcombe, president and CEO, vTv Therapeutics. “We
believe that these results, if confirmed in the larger, on-going
portion of the study, would strongly position TTP399 for phase 3
development to help address the needs of patients suffering with
T1D.”
A copy of the poster is available on the company website at
http://vtvtherapeutics.com/publications/.
About the Simplici-T1 Study:
Simplici-T1 is a multi-center, randomized, double-blind,
adaptive study assessing the pharmacokinetics, pharmacodynamics,
safety and tolerability of TTP399 as an adjunct to insulin therapy
in adult patients with T1D. The study is being conducted with
support from JDRF, the leading global organization funding research
in type 1 diabetes.
The Phase 2 learn-and-confirm study is being conducted in two
parts to evaluate the safety and efficacy of TTP399 in T1D patients
over twelve weeks of daily dosing. Part 1 enrolled 19 patients on
both insulin pumps and CGMs. The topline results from Phase 2 -
Part 1 were reported in June 2019:
- The study met its primary endpoint of change in A1c from
baseline after 12 weeks of treatment. Patients treated with TTP399
(n=8) showed a statistically significant mean reduction in HbA1c of
0.7% (p=0.03) at 12 weeks relative to the placebo group
(n=11).
- TTP399 was well tolerated with similar incidences of
treatment-emergent adverse events overall and by system organ
class. The study had neither a serious adverse event nor an
incident of diabetic ketoacidosis reported.
Part 2 is now fully-enrolled with patients utilizing a treatment
regimen that includes either insulin pumps or multiple daily
injection therapy, with CGMs optional. Topline results from the
study are expected in the first quarter of 2020.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical
company focused on developing oral small molecule drug candidates.
vTv has a pipeline of clinical drug candidates led by programs for
the treatment of diabetes, Alzheimer’s disease, and inflammatory
disorders. vTv’s development partners are pursuing additional
indications in type 2 diabetes, chronic obstructive pulmonary
disease (COPD), and genetic mitochondrial diseases.
Forward-Looking Statements
This release contains forward-looking statements, which involve
risks and uncertainties. These forward-looking statements can be
identified by the use of forward-looking terminology, including the
terms “anticipate,” “believe,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and, in each case, their
negative or other various or comparable terminology. All statements
other than statements of historical facts contained in this
release, including statements regarding the timing of our clinical
trials, our strategy, future operations, future financial position,
future revenue, projected costs, prospects, plans, objectives of
management and expected market growth are forward-looking
statements. These statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Important factors that
could cause our results to vary from expectations include those
described under the heading “Risk Factors” in our Annual Report on
Form 10-K and our other filings with the SEC. These forward-looking
statements reflect our views with respect to future events as of
the date of this release and are based on assumptions and subject
to risks and uncertainties. Given these uncertainties, you should
not place undue reliance on these forward-looking statements. These
forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law,
we undertake no obligation to update or review publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise after the date of this release. We
anticipate that subsequent events and developments will cause our
views to change. Our forward-looking statements do not reflect the
potential impact of any future acquisitions, merger, dispositions,
joint ventures or investments we may undertake. We qualify all of
our forward-looking statements by these cautionary statements.
ContactsInvestors: vTv Therapeutics Inc.
IR@vtvtherapeutics.com
or Media:Josh Vlasto212-572-5969PR@vtvtherapeutics.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Aug 2024 to Sep 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Sep 2023 to Sep 2024